-
A Breakthrough for Rare Disease: FDA Approves Joenja for APDS
NASDAQ: $PHAR A New Chapter for Families Affected by APDS In a significant milestone for medical science, the U.S. Food and Drug Administration (FDA) has officially approved Joenja (leniolisib). This approval marks a historic moment as the first-ever treatment specifically indicated for patients 12 years of age and older diagnosed with Activated Phosphoinositide 3-kinase delta…
-
A New Hope: FDA Approves Atrebioz (zilurgisertib) for FOP Treatment
NASDAQ: $MIRM A Breakthrough for Rare Disease Patients The landscape of treatment for Fibrodysplasia Ossificans Progressiva (FOP) has officially changed. The FDA has recently approved Atrebioz (zilurgisertib), providing a significant new therapeutic option for both adult and pediatric patients living with this incredibly rare and debilitating condition. Understanding FOP FOP is a progressive genetic disorder…
-
New Two-Year Data Supports Long-Term Management of Classic Congenital Adrenal Hyperplasia with CRENESSITY®
NASDAQ: $NBIX For individuals living with classic congenital adrenal hyperplasia (CAH), the standard of care has long presented a difficult dilemma. While patients require glucocorticoids (GCs) to survive, the historical reliance on supraphysiologic doses—doses higher than what the body naturally produces—has carried a heavy burden of long-term health risks, including metabolic complications, bone density loss,…